MedTrace Logo

sCD163 in PBC Patients - Assessment of Treatment Response

NCT02931513 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-08-12

No results posted yet for this study

Summary

Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment.

sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR can predict response to treatment with UDCA in newly diagnosed patients with PBC.

Conditions

  • Primary Biliary Cirrhosis
  • Liver Inflammation
  • Ursodeoxycholic Acid

Interventions

OTHER

Blood samples

DEVICE

Fibroscan

OTHER

Questionnaires

BIOLOGICAL

Liver biopsy

Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2031-01-31
Completion
2031-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02931513 on ClinicalTrials.gov